Foundation Medicine announced it has extended and expanded its ongoing collaboration with Novartis to provide molecular information and comprehensive genomic profiling analysis in support of many of Novartis' clinical oncology programs. The collaboration will now extend through at least September 2016. As the result of Foundation Medicine and Novartis' pilot program established in January 2011 and an expanded three-year agreement in June 2012, Foundation Medicine's comprehensive genomic profiling has generated clinically relevant data and is now regularly used in many of Novartis' oncology clinical trials. This new agreement, which the companies agreed to extend and expand prior to the end of the existing term, includes committed capacity for Foundation Medicine to provide genomic profiling of patient samples from Novartis clinical trials, as well as access to Foundation Medicine's molecular information and analysis services.

The new three-year agreement also gives Novartis the option to extend the term for an additional two-year period. Financial terms are not being disclosed.